Outlook Therapeutics Inc OTLK:NASDAQ

Last Price$1.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/18/22

Today's Change-0.01(0.83%)
Bid (Size)$1.19 (11)
Ask (Size)$1.30 (7)
Day Low / High$1.16 - 1.26
Volume284.8 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/18/2022

 

Outlook Therapeutics Inc ( NASDAQ )

Price: $1.20
Change: -0.01 (0.83%)
Volume: 284.8 K
4:00PM ET 8/18/2022
 
 

Rigel Pharmaceuticals Inc ( NASDAQ )

Price: $1.62
Change: +0.03 (1.89%)
Volume: 5.6 M
4:00PM ET 8/18/2022
 
 

MacroGenics Inc ( NASDAQ )

Price: $4.40
Change: -0.09 (2.00%)
Volume: 501.0 K
4:00PM ET 8/18/2022
 
 

Aveo Pharmaceuticals Inc ( NASDAQ )

Price: $7.69
Change: -0.05 (0.65%)
Volume: 253.8 K
4:00PM ET 8/18/2022
 
 

Evelo Biosciences Inc ( NASDAQ )

Price: $2.68
Change: +0.08 (3.08%)
Volume: 84.9 K
4:00PM ET 8/18/2022
 

Read more news Recent News

Sector Update: Health Care Stocks Struggle Tuesday
4:09PM ET 7/05/2022 MT Newswires

Health care stocks continued to sputter this afternoon, with the NYSE Health Care Index sinking 0.8% and the SPDR Health Care Select Sector ETF (XLV) down...

Sector Update: Health Care Stocks Retreating in Tuesday Trade
1:44PM ET 7/05/2022 MT Newswires

Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 2.2% and the SPDR Health Care Select Sector ETF (XLV) down...

Outlook Therapeutics Makes Full Cash Pre-Payment of Convertible Promissory Note; Shares Rise Midday
12:29PM ET 7/05/2022 MT Newswires

Outlook Therapeutics (OTLK) said Tuesday that it made a full cash pre-payment of its unsecured convertible promissory note dated Nov. 4, 2020, and that all...

Outlook Therapeutics to Refile Biologics License Application With FDA for ONS-5010 by September; Shares Rise
9:47AM ET 6/14/2022 MT Newswires

Outlook Therapeutics (OTLK) said Tuesday it expects to re-submit the biologics license application for ONS-5010 to treat wet age-related macular...

View all Commentary and Analysis

Outlook Therapeutics: A One-Buck Lottery Ticket
2:27PM ET 6/09/2022 Seeking Alpha

Outlook Therapeutics (OTLK) Investor Presentation - Slideshow
4:48PM ET 5/13/2022 Seeking Alpha

Outlook Therapeutics: Likely FDA Approval, Possible Buyout
2:00PM ET 1/21/2022 Seeking Alpha

Wall Street Breakfast: The Week Ahead (Podcast)
7:21AM ET 10/10/2021 Seeking Alpha

Company Profile

Business DescriptionOutlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ. View company web site for more details
Address485 Route 1 South
Iselin, New Jersey 08830
Phone+1.609.619.3990
Number of Employees56
Recent SEC Filing08/15/20223
President, Chief Executive Officer & DirectorC. Russell Trenary
Chief Operating OfficerTerry Dagnon
CFO, Secretary, Treasurer & DirectorLawrence A. Kenyon
Senior Vice President-Clinical DevelopmentJennifer M. Kissner

Company Highlights

Price Open$1.21
Previous Close$1.21
52 Week Range$0.68 - 2.87
Market Capitalization$271.4 M
Shares Outstanding226.1 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement12/28/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.32
Beta vs. S&P 500N/A
Revenue$3.1 M
Net Profit MarginN/A
Return on Equity-237.90%

Analyst Ratings as of 02/14/2022

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset